Drug Profile

SIM 0500

Alternative Names: SIM-0500

Latest Information Update: 22 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Simcere Pharmaceutical Group
Class Antineoplastics; Immunotherapies; Trispecific antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Multiple myeloma

Most Recent Events

13 Jan 2025 Simcere Zaiming and AbbVie agree to co-develop SIM 0500 with an option to license in China for Multiple myeloma
13 Jan 2025 Pharmacodynamics data from a Preclinical trial in Multiple myeloma released by Simcere Zaiming
24 May 2024 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (Parenteral) (NCT06375044)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com